Trial Profile
An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies [EXTENSION OF 700242999 and 700243076]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Apr 2014
Price :
$35
*
At a glance
- Drugs Corticorelin (Primary)
- Indications Brain oedema
- Focus Adverse reactions; Registrational
- Sponsors Celtic Pharma
- 10 Apr 2014 New trial record
- 29 Apr 2009